The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Bristol-Myers Squibb; Cellectis; Daiichi Sankyo; ImmunoGen; Incyte; Janssen; Jazz Pharmaceuticals; Menarini; Novartis; Otsuka; Pfizer; SERVIER; Shire; Sunesis Pharmaceuticals
Research Funding - Amgen (Inst); Incyte (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); SERVIER (Inst)
Health-related quality of life (HRQoL) in the phase III QUAZAR-AML-001 trial of CC-486 as maintenance therapy for patients with acute myeloid leukemia (AML) in first remission following induction chemotherapy (IC).
 
Gail J. Roboz
Consulting or Advisory Role - Abbvie; Actinium Pharmaceuticals; Agios; Amgen; Amphivena; argenx; Array BioPharma; Astellas Pharma; Astex Pharmaceuticals; Bayer; Bayer; Celgene; Celltrion; Daiichi Sankyo; Eisai; Genentech/Roche; Genoptix; Janssen; Jazz Pharmaceuticals; MedImmune; MEI Pharma; Novartis; Orsenix; Otsuka; Pfizer; Roche; Sandoz; Takeda; Trovagene
Research Funding - Abbvie (Inst); Agios (Inst); amphivena (Inst); Astex Pharmaceuticals (Inst); Celgene (Inst); Cellectis (Inst); Cellectis (Inst); CTI (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); MEI Pharma (Inst); Moffitt (Inst); Novartis (Inst); Onconova Therapeutics (Inst); Pfizer (Inst); Sunesis Pharmaceuticals (Inst); Tensha Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; Agios; Amgen; Amphivena; Array BioPharma; Astex Pharmaceuticals; Bayer; Celgene; Celltrion; Clovis Oncology; Eisai; Janssen; Jazz Pharmaceuticals; Novartis; Pfizer; Roche/Genentech; Sandoz; Sunesis Pharmaceuticals
 
Hartmut Dohner
Honoraria - Abbvie; Celgene; Jazz Pharmaceuticals; Novartis
Consulting or Advisory Role - Abbvie; Agios; Amgen; Astellas Pharma; Astex Pharmaceuticals; Celgene; Jazz Pharmaceuticals; Roche
Research Funding - Amgen (Inst); Arog (Inst); Bristol-Myers Squibb (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Sunesis Pharmaceuticals (Inst)
 
Christopher Pocock
Consulting or Advisory Role - AstraZeneca
 
Hervé Dombret
No Relationships to Disclose
 
Farhad Ravandi
Honoraria - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; Celgene; Orsenix; Pfizer; Seagen; Sunesis Pharmaceuticals
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; Celgene; Jazz Pharmaceuticals; Orsenix; Seagen; Sunesis Pharmaceuticals
Research Funding - Amgen; Bristol-Myers Squibb; Cellerant; Macrogenics; Merck; Seagen; Selvita; Sunesis Pharmaceuticals; Xencor
 
Jun Ho Jang
No Relationships to Disclose
 
Dominik Selleslag
Honoraria - Abbvie; Alexion Pharmaceuticals; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Janssen-Cilag; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi; Takeda; Teva
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen-Cilag; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi; Takeda; Teva
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Takeda; Teva
(OPTIONAL) Uncompensated Relationships - Belgian college for reimbursement of orphan drugs (Inst)
 
Jiri Mayer
Research Funding - Bristol-Myers Squibb (Inst)
 
Uwe Marc Martens
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; MSD Oncology; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Pierre Fabre
 
Jane Liesveld
Honoraria - Abbvie
Other Relationship - Onconova Therapeutics
 
Teresa Bernal del Castillo
No Relationships to Disclose
 
Ming-Chung Wang
No Relationships to Disclose
 
Ignazia La Torre
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Barry Skikne
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Keshava Kumar
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Qian Dong
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Julia Braverman
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Salem Abi Nehme
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
C. L. Beach
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Andrew Wei
Honoraria - Abbvie/Genentech; Amgen; Celgene; Janssen Oncology; Novartis; Pfizer; Roche; SERVIER
Consulting or Advisory Role - Abbvie/Genentech; Amgen; Celgene; Macrogenics; Novartis; Pfizer; SERVIER
Speakers' Bureau - Abbvie/Genentech; Amgen; Celgene; Novartis
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Novartis (Inst); Servier (Inst)
Patents, Royalties, Other Intellectual Property - AW is a former employee of the Walter and Eliza Hall Institute which receives milestone and royalty payments related to venetoclax, and is eligible for benefits related to these payments. AW receives payments from WEHI related to venetoclax
Travel, Accommodations, Expenses - Abbvie; Amgen; Celgene; Janssen Oncology; Novartis; Pfizer; Servier